B. Laube et al., Establishment of a novel in vitro system for studying the interaction of xenobiotic metabolism of liver and intestinal microflora, ARCH TOXIC, 74(7), 2000, pp. 379-387
We developed a new two-chamber system for the coculture of hepatocytes and
fecal microflora under aerobic and anaerobic conditions, respectively, to i
nvestigate the sequential metabolism of chemicals by the liver and microflo
ra in vitro. The culture device consisted of two chambers separated by a pe
rmeable polycarbonate membrane. In the aerobic compartment, hepatocytes wer
e cultivated as a monolayer on the membrane and in the anaerobic compartmen
t fecal microflora as a suspension. To characterize the metabolic capacity
of the microflora and hepatocytes, various marker enzymes were studied. Azo
reductase, nitroductase, beta-glucuronidase, beta-glucosidase and sulphatas
e were tested in the microflora of the feces from three volunteers who had
had significantly different eating habits for years (daily meat, mixed diet
, vegetarian). The microflora exhibited significant activities and the vari
ous enzymes differed only moderately in the samples from the three voluntee
rs. For rat hepatocytes the activities of various cytochrome P450 forms and
conjugating enzymes served as markers. The enzyme activities were tested i
n the coculture system during a 4-h culture period intended for the test pr
otocol. Deethylation of ethoxycoumarin and 2 alpha-, 6 beta- and 16 alpha-h
ydroxylation of testosterone decreased by about 30%, 25%. 40% and 20%, resp
ectively, while there was no loss of glucuronidation and sulphonation of 3-
OH-benzo(a)pyrene nor of glutathione conjugation of 1-chloro-2,4-dinitroben
zene during the 4-h culture period. The activities of the tested hepatic ph
ase I and II enzymes were not changed after coculture of the hepatocytes wi
th the microflora for 4 h. The applicability of the in vitro system for stu
dying the metabolic interaction of liver and microflora was demonstrated us
ing 7-ethoxycoumarin and the developmental drug EMD 57033, a thiadiazinon d
erivative from Merck KGaA, as model compounds. Both compounds were oxidized
and conjugated by liver cells. In the coculture of hepatocytes and fecal m
icroflora the resulting glucuronides and sulphoconjugates were split by hyd
rolytic enzymes of the intestinal microflora.